Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 3,400 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average price of $19.89 per share, with a total value of $67,626.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Xencor, Inc. (XNCR) opened at $20.42 on Tuesday. Xencor, Inc. has a 52 week low of $18.55 and a 52 week high of $29.38.

WARNING: “Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 3,400 Shares of Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/14/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-acquires-3400-shares-of-stock.html.

Large investors have recently added to or reduced their stakes in the business. Equitec Specialists LLC acquired a new position in Xencor during the second quarter worth $116,000. Great West Life Assurance Co. Can lifted its stake in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,005 shares in the last quarter. SG Americas Securities LLC lifted its stake in Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 3,252 shares in the last quarter. Principal Financial Group Inc. acquired a new position in Xencor during the third quarter worth $201,000. Finally, Legal & General Group Plc lifted its stake in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares in the last quarter. Institutional investors own 76.70% of the company’s stock.

Several research analysts recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research report on Sunday. Finally, BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.25.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.